Compare Johnson Controls International PLC (JCI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Travere Therapeutics Inc. Common Stock — how do they compare? Johnson Controls International PLC trades at $151.51 (market cap $94.78B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Johnson Controls International PLC is far larger — about 19.4× Travere Therapeutics Inc. Common Stock's market cap, and Johnson Controls International PLC pays a 1.02% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JCI | TVTX | |
|---|---|---|
Market Cap | $94.78B | $4.88B |
Volume | 4,103,814 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $67.52 |
52-Week Low | $108.54 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $103.61B | $5.01B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $152.44, down 1.91% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.42 beating estimates of $1.30, maintaining a three-quarter beat streak. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong Q3 2026 results with 10% organic sales growth and raised full-year guidance.
JCI presents a compelling investment case with analyst consensus strongly bullish (62% buy ratings) and a $172.50 price target offering 13% upside. Key opportunities include strong demand for data-center thermal management systems and expanding profit margins. Risks include elevated valuation multiples (P/E 44.08) and increasing debt-to-asset ratio (26.06% in 2025). The stock's technical position near key support at $153 requires monitoring for sustained bullish momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
